The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation

The biotransformation pathway of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species was investigated in rat hepatocytes in vitro. Rat hepatocytes were isolated by in situ collagenase perfusion and then maintained in sulphate-free Dulbecco's modified Eagle's medium. Magnesium sulphate was added to the medium to give concentrations of 0-10 microM, prior to treatment for 18 h with solvent vehicle (DMSO), tamoxifen (10 microM), alpha-hydroxytamoxifen (1 microM) or benzo[a]pyrene (BaP) (10 and 50 microM). DNA was isolated and analysed by 32P-post-labelling. For tamoxifen and alpha-hydroxytamoxifen, the level of DNA adduct formation was directly proportional to the concentration of sulphate in the medium. Between 0 and 10 microM MgSO4, the DNA adduct level increased 10-fold with both compounds. Rat hepatocytes were also maintained in normal Dulbecco's modified Eagle's medium and pretreated with dehydroisoandrosterone-3-sulphate (DHEAS, a sulphotransferase inhibitor) at concentrations ranging from 0-1 mM, prior to treatment with solvent vehicle (DMSO), tamoxifen (10 microM), alpha-hydroxytamoxifen (1 microM) or BaP (50 microM). For tamoxifen and alpha-hydroxytamoxifen the level of DNA adducts was reduced to approximately one-fifth by the addition of DHEAS (0.1 mM). BaP-DNA adduct formation, which proceeds by a pathway that does not require sulphation, was not significantly affected by sulphate concentration or by addition of DHEAS, which demonstrates that the general metabolic capacity and viability of the hepatocytes were not compromised. It is concluded that the activation of tamoxifen in rat liver cells to DNA binding products proceeds predominantly through hydroxylation followed by sulphate ester formation at the alpha-position of the ethyl side chain.